Bausch Health Companies Inc

Bausch Health Companies Inc (BHC)

$8.2

-0.01

(-0.12%)

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Bausch Health Companies Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 2.13B → 1.94B (in $), with an average decrease of 9.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -410.0M → -201.0M (in $), with an average increase of 104.0% per quarter

  • Vs ZTS

    In the last 1 year, Bausch Health Companies Inc has experienced a drawdown of -14.2%, however Zoetis Inc - Class A resisted the overall trend and outperformed by 11.8%

  • Vs ZTS

    In the last 3 years, Zoetis Inc - Class A has given 17.8% return, outperforming this stock by 75.0%

Performance

  • $8.03
    $8.29
    $8.20
    downward going graph

    2.07%

    Downside

    Day's Volatility :3.08%

    Upside

    1.03%

    downward going graph
  • $4.00
    $10.23
    $8.20
    downward going graph

    51.22%

    Downside

    52 Weeks Volatility :60.9%

    Upside

    19.84%

    downward going graph

Returns

PeriodBausch Health Companies IncSector (Health Care)Index (Russel 2000)
3 Months
-10.95%
0.7%
-6.8%
6 Months
6.62%
-8.3%
-6.0%
1 Year
-14.21%
-1.9%
-4.6%
3 Years
-57.15%
25.3%
25.9%

Highlights

Market Capitalization
3.0B
Book Value
- $2.2
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-0.97
PEG Ratio
0.63
Wall Street Target Price
13.1
Profit Margin
-4.38%
Operating Margin TTM
16.92%
Return On Assets TTM
3.16%
Return On Equity TTM
-17750.0%
Revenue TTM
8.2B
Revenue Per Share TTM
22.48
Quarterly Revenue Growth YOY
1.4000000000000001%
Gross Profit TTM
5.8B
EBITDA
2.7B
Diluted Eps TTM
-0.97
Quarterly Earnings Growth YOY
1.12
EPS Estimate Current Year
3.29
EPS Estimate Next Year
3.78
EPS Estimate Current Quarter
0.72
EPS Estimate Next Quarter
0.79

Analyst Recommendation

Buy
    62%Buy
    37%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Bausch Health Companies Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
5
6
Hold
3
3
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 59.76%

Current $8.20
Target $13.10

Company Financials

FY17Y/Y Change
Revenue
8.7B
↓ 9.82%
Net Income
2.4B
↓ 199.79%
Net Profit Margin
27.56%
↑ 52.46%
FY18Y/Y Change
Revenue
8.4B
↓ 3.94%
Net Income
-4.1B
↓ 272.55%
Net Profit Margin
-49.5%
↓ 77.06%
FY19Y/Y Change
Revenue
8.6B
↑ 2.64%
Net Income
-1.8B
↓ 56.89%
Net Profit Margin
-20.79%
↑ 28.71%
FY20Y/Y Change
Revenue
8.0B
↓ 6.67%
Net Income
-560.0M
↓ 68.68%
Net Profit Margin
-6.98%
↑ 13.81%
FY21Y/Y Change
Revenue
8.4B
↑ 5.07%
Net Income
-948.0M
↑ 69.29%
Net Profit Margin
-11.24%
↓ 4.26%
FY22Y/Y Change
Revenue
8.0B
↓ 4.6%
Net Income
-225.0M
↓ 76.27%
Net Profit Margin
-2.8%
↑ 8.44%
Q4 FY21Q/Q Change
Revenue
2.2B
↑ 4.03%
Net Income
69.0M
↓ 63.3%
Net Profit Margin
3.14%
↓ 5.77%
Q1 FY22Q/Q Change
Revenue
1.9B
↓ 12.66%
Net Income
-69.0M
↓ 200.0%
Net Profit Margin
-3.6%
↓ 6.74%
Q2 FY22Q/Q Change
Revenue
1.9B
↑ 1.51%
Net Income
-145.0M
↑ 110.14%
Net Profit Margin
-7.45%
↓ 3.85%
Q3 FY22Q/Q Change
Revenue
2.0B
↑ 5.08%
Net Income
399.0M
↓ 375.17%
Net Profit Margin
19.5%
↑ 26.95%
Q4 FY22Q/Q Change
Revenue
2.1B
↑ 4.35%
Net Income
-410.0M
↓ 202.76%
Net Profit Margin
-19.2%
↓ 38.7%
Q1 FY23Q/Q Change
Revenue
1.9B
↓ 8.95%
Net Income
-201.0M
↓ 50.98%
Net Profit Margin
-10.34%
↑ 8.86%
FY17Y/Y Change
Total Assets
37.5B
↓ 13.86%
Total Liabilities
31.6B
↓ 21.65%
FY18Y/Y Change
Total Assets
32.5B
↓ 13.35%
Total Liabilities
29.7B
↓ 5.95%
FY19Y/Y Change
Total Assets
33.9B
↑ 4.22%
Total Liabilities
32.7B
↑ 10.28%
FY20Y/Y Change
Total Assets
31.2B
↓ 7.87%
Total Liabilities
30.6B
↓ 6.52%
FY21Y/Y Change
Total Assets
29.2B
↓ 6.4%
Total Liabilities
29.2B
↓ 4.44%
FY22Y/Y Change
Total Assets
25.7B
↓ 12.04%
Total Liabilities
25.4B
↓ 13.03%
Q4 FY21Q/Q Change
Total Assets
29.2B
↓ 0.17%
Total Liabilities
29.2B
↓ 0.51%
Q1 FY22Q/Q Change
Total Assets
29.1B
↓ 0.38%
Total Liabilities
29.2B
↓ 0.02%
Q2 FY22Q/Q Change
Total Assets
28.2B
↓ 3.16%
Total Liabilities
27.9B
↓ 4.49%
Q3 FY22Q/Q Change
Total Assets
26.3B
↓ 6.65%
Total Liabilities
25.9B
↓ 7.35%
Q4 FY22Q/Q Change
Total Assets
25.7B
↓ 2.33%
Total Liabilities
25.4B
↓ 1.7%
Q1 FY23Q/Q Change
Total Assets
25.4B
↓ 0.94%
Total Liabilities
25.3B
↓ 0.5%
FY17Y/Y Change
Operating Cash Flow
2.3B
↑ 9.73%
Investing Cash Flow
2.9B
↓ 2409.6%
Financing Cash Flow
-5.0B
↑ 152.83%
FY18Y/Y Change
Operating Cash Flow
1.5B
↓ 34.45%
Investing Cash Flow
-196.0M
↓ 106.79%
Financing Cash Flow
-1.4B
↓ 72.74%
FY19Y/Y Change
Operating Cash Flow
1.5B
↑ 0.0%
Investing Cash Flow
-419.0M
↑ 113.78%
Financing Cash Flow
1.4B
↓ 206.65%
FY20Y/Y Change
Operating Cash Flow
1.1B
↓ 25.98%
Investing Cash Flow
-261.0M
↓ 37.71%
Financing Cash Flow
-2.3B
↓ 258.97%
FY21Y/Y Change
Operating Cash Flow
1.4B
↑ 28.35%
Investing Cash Flow
409.0M
↓ 256.7%
Financing Cash Flow
-1.5B
↓ 34.05%
Q4 FY21Q/Q Change
Operating Cash Flow
24.0M
↓ 95.74%
Investing Cash Flow
-80.0M
↓ 113.61%
Financing Cash Flow
275.0M
↓ 123.77%
Q1 FY22Q/Q Change
Operating Cash Flow
-63.0M
↓ 362.5%
Investing Cash Flow
-56.0M
↓ 30.0%
Financing Cash Flow
468.0M
↑ 70.18%
Q2 FY22Q/Q Change
Operating Cash Flow
123.0M
↓ 295.24%
Investing Cash Flow
-58.0M
↑ 3.57%
Financing Cash Flow
-630.0M
↓ 234.62%
Q3 FY22Q/Q Change
Operating Cash Flow
-1.3B
↓ 1126.83%
Investing Cash Flow
-167.0M
↑ 187.93%
Financing Cash Flow
-36.0M
↓ 94.29%
Q1 FY23Q/Q Change
Operating Cash Flow
154.0M
↓ 67.58%
Investing Cash Flow
-78.0M
-
Financing Cash Flow
-142.0M
↓ 48.55%

Technicals Summary

Sell

Neutral

Buy

Bausch Health Companies Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Bausch Health Companies Inc
Bausch Health Companies Inc
9.32%
6.62%
-14.21%
-57.15%
-62.82%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-13.93%
-29.12%
-3.47%
-27.45%
-9.1%
Zoetis Inc.
Zoetis Inc.
-9.22%
4.07%
-2.4%
17.83%
90.83%
Viatris Inc.
Viatris Inc.
-2.24%
-18.59%
-24.19%
-44.0%
-44.0%
Catalent, Inc.
Catalent, Inc.
-25.72%
-28.72%
-64.37%
-51.42%
-6.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Bausch Health Companies Inc
Bausch Health Companies Inc
71.75
NA
0.63
3.29
-177.5
0.03
0.0
-2.2
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
145.34
145.34
1.87
2.1
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
36.41
36.41
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.8
5.8
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
15.88
15.88
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Bausch Health Companies Inc
Bausch Health Companies Inc
Buy
$3.0B
-62.82%
71.75
-4.38%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$8.8B
-9.1%
145.34
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$74.4B
90.83%
36.41
25.59%
Viatris Inc.
Viatris Inc.
Hold
$10.9B
-44.0%
5.8
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.5B
-6.08%
15.88
8.62%

Institutional Holdings

  • ICAHN CARL C

    9.55%
  • Paulson & Company Inc

    7.27%
  • Franklin Resources Inc

    4.57%
  • Goldentree Asset Management LP

    4.55%
  • Natixis SA

    4.35%
  • Hudson Bay Capital Management LP

    3.16%

Company Information

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Organization
Bausch Health Companies Inc
Employees
19900
CEO
Mr. Thomas J. Appio
Industry
Health Technology

FAQs